Maxim Group affirmed their Buy rating on Tekmira Pharmaceuticals Corp. (Nasdaq: TKMR) and lifted their price target from $23 to $31 sending the stock price soaring $4.06 to close at $29.53.
Tekmira price target lifted
October 03, 2014 at 17:12 PM EDT
